CD8α Structural Domains Enhance GUCY2C CAR-T Cell Efficacy
Despite success in treating some hematological malignancies, CAR-T cells have not yet produced similar outcomes in solid tumors due, in part, to the tumor microenvironment, poor persistence, and a paucity of suitable target antigens. Importantly, the impact of the CAR components on these challenges...
Saved in:
| Main Authors: | Trevor R. Baybutt, Ariana A. Entezari, Adi Caspi, Ross E. Staudt, Robert D. Carlson, Scott A. Waldman, Adam E. Snook |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2024.2398801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR-T: from bench to bedside
by: M. О. Popova, et al.
Published: (2024-09-01) -
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01) -
Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01) -
Chimeric Autoantibody Receptor- and/or Peptide-MHC-Based CAR Therapies for Targeted Elimination of Antigen-Specific B or T Cells in Hypersensitivity Disorders Such as Allergies and Autoimmune Diseases
by: Isidora Protić-Rosić, et al.
Published: (2025-05-01) -
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)